|
LONRF2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62447832963153E-12 |
| Normal-vs-Stage2 |
5.9532999999945E-05 |
| Normal-vs-Stage3 |
2.19699813897023E-11 |
| Normal-vs-Stage4 |
1.270699999667E-07 |
| Stage1-vs-Stage2 |
8.080000E-01 |
| Stage1-vs-Stage3 |
2.158400E-01 |
| Stage1-vs-Stage4 |
8.421200E-01 |
| Stage2-vs-Stage3 |
3.849000E-01 |
| Stage2-vs-Stage4 |
9.424400E-01 |
| Stage3-vs-Stage4 |
2.871000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62436730732907E-12 |
| Normal-vs-AfricanAmerican |
6.366700E-04 |
| Normal-vs-Asian |
3.79250000293041E-08 |
| Caucasian-vs-AfricanAmerican |
9.922600E-01 |
| Caucasian-vs-Asian |
5.669800E-01 |
| AfricanAmerican-vs-Asian |
7.261400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.43911615536308E-13 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
3.764100E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(61-80Yrs) |
1.02860000517069E-08 |
| Normal-vs-Age(81-100Yrs) |
1.962850E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.911800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.568800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.603910E-04 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.481800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.155300E-04 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.827990E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.306570E-01 |
| Classical-VS-Follicular |
1.184870E-04 |
| Classical-VS-Other |
1.780210E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
4.596000E-01 |
| Tall-VS-Other |
4.857600E-01 |
| Tall-VS-Normal |
2.599300E-04 |
| Follicular-VS-Other |
7.731800E-01 |
| Follicular-VS-Normal |
1.78829999997188E-06 |
| Other-VS-Normal |
1.185400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62836411021772E-12 |
| Normal-vs-N1 |
2.89829999999824E-08 |
| N0-vs-N1 |
9.969200E-01 |
|
|
